Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 7.55 -0.35 (4.43%)
Day High: 7.97
Day Low:  7.49
Volume:    323,912
4:00 PM ET
Jun 26, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

May 31, 2017 / 10:00 AM ET